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Abstract  
Although the mechanism(s) are largely unidentified, the chronic or intermittent 
hypoxic patterns occurring with respiratory diseases, such as chronic pulmonary 
disease or obstructive sleep apnea (OSA) and obesity, are commonly associated with 
glucose intolerance. Indeed, hypoxia has been widely implicated in the development 
of insulin resistance either via the direct action on insulin receptor substrate (IRS) and 
protein kinase B (PKB/Akt) or indirectly through adipose tissue expansion and 
systemic inflammation. Yet hypoxia is also known to encourage glucose transport 
using insulin-dependant mechanisms, largely reliant on the metabolic master switch, 
5' AMP-activated protein kinase (AMPK). In addition, hypoxic exposure has been 
shown to improve glucose control in type 2 diabetics. The literature surrounding 
hypoxia-induced changes to glycemic control appear confusing and conflicting. How 
is it that the same stress can seemingly cause insulin resistance while increase glucose 
uptake? There is little doubt that acute hypoxia increases glucose metabolism in 
skeletal muscle and does so using the same pathway as muscle contraction. The 
purpose of this review paper is to provide an insight into the mechanisms 
underpinning the observed effects and to open up discussions around the conflicting 
data surrounding hypoxia and glucose control. 
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Introduction 
Type 2 diabetes is a metabolic disease categorized, primarily, by reduced insulin 
sensitivity, β-cell dysfunction, and elevated hepatic glucose production [1]. Insulin 
resistance is widely accepted as the starting point for the progression from glucose 
intolerance to overt type 2 diabetes. Therefore understanding the underlining 
mechanisms of insulin resistance pathophysiology is of great importance to the 
development of novel and effective treatments.  
Peripheral insulin resistance represents a decrease in insulin-dependent glucose 
transport in insulin responsive tissues [2] (Dinneen et al., 1992), which can be the 
product of defects at both the insulin receptor and / or post-receptor signaling [3]. 
Inflammation [4-7], hyperglycemia [8, 9], sulinaemia [10, 11] hyperlipidaemia [12, 
13] and hypoxia [14-16] have all been linked to the development of insulin resistance 
and type 2 diabetes. Indeed, hypoxia has been widely implicated in the development 
of insulin resistance either via the direct action on insulin receptor substrate (IRS) 
[17] and protein kinase B (PKB; also known as Akt) [18, 19] or indirectly through 
adipose tissue expansion [20] and systemic inflammation [21, 22]. However, we 
demonstrated that acute hypoxic exposure increases two-compartment models of 
insulin sensitivity (SI
2*
) in human type 2 diabetics [23] with Lecoultre et al. [93] 
showing that ten nights of moderate hypoxic exposure improved insulin sensitivity in 
obese males, as measured by the 2-step hyperinsulinemic-euglycemic clamp method. 
This data highlights some of the controversy over the role hypoxia plays in glucose 
control and metabolism. Interestingly, the same work showed that muscle expression 
of Akt and IRS1 was not affected by the hypoxic treatment [93]. 
The purpose of this review is to consider the literature while providing roles for 
hypoxia  in causing insulin resistance and glucose intolerance. Furthermore, this 
review will discuss hypoxia’s apparent dual ability to increase glucose transport 
activity acutely in skeletal muscle, using a pathway independent to insulin, and 
dissect why hypoxia is also implicated in insulin resistance. Providing a greater 
understanding of the metabolic responses to hypoxia has genuine clinical relevance 
and may open up future therapeutic methods in the treatments of glucose intolerance 
and type 2 diabetes. 
 
The evidence surrounding hypoxic-induced insulin resistance 
The observation that insulin resistance and glucose intolerance are positively 
correlated with hypoxia originates from studies by Strohl et al.  in 1994 [28]. These 
authors suggested that sleep apnoea was independently associated with body mass 
index (BMI) and insulin dysregulation [28]. The chronic or intermittent hypoxia 
patterns occurring with respiratory diseases, such as chronic pulmonary disease or 
obstructive sleep apnea (OSA), are commonly cited as potential causes of glucose 
intolerance [25-27], an early indication of a disruption in normal glycemic control. 
The link between respiratory diseases and insulin resistance is complex. Oltmann et al. 
[16] clearly showed that glucose infusion rates are reduced in response to a 30 
minutes period of sustained hypoxia (oxygen saturations levels ~75%). The authors 
attribute this to a sympathoadrenal-induced epinephrine release, resulting in increased 
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hepatic glucose production and a reduction in glucose disposal at insulin sensitive 
peripheral tissue [16]. In addition, epinephrine has been shown to inhibit insulin-
stimulated glucose uptake in rat skeletal muscle by reducing glucose phosphorylation 
[29].  The hypoxic stimulus used in Oltmanns et al., [16] work is likely to have 
increased hepatic glucose appearance [30] in an attempt to off-set a change in 
peripheral tissue fuel utilization towards glucose metabolism. The consequence would 
therefore be a reduction in dextrose infusion rates [16] and a decrease in insulin 
mediated glucose uptake [29]. Indeed, epinephrine causes GLUT-4 translocation yet 
inhibits insulin-mediated glucose disposal skeletal muscle [31]. Thus the responses 
described might reflect a transient change in metabolic processes and not chronic 
changes in insulin resistance.  
 
Brooks et al. (1991) showed that insulin concentrations were elevated in healthy 
individuals upon arrival to high altitude (4,300 metres) [32], suggesting that hypoxia 
may cause glucose intolerance or at the very least, disrupt glucose metabolism. 
However this is hard to conclude without access to c-peptide measures, which were 
not presented in this work [32]. Furthermore, the rise in blood insulin values may 
actually be a product of reduced insulin action rather than decreased glucose uptake. 
In more recent work, Louis & Punjabi [33] demonstrated a reduction in one-
compartment models of insulin sensitivity (SI) and insulin secretion in response to 5 
hours of intermittent hypoxia, a treatment used to replicate OSA. In this study it was 
suggested that increased sympathetic nervous activity, in response to intermittent 
hypoxia decreased glycogenesis, increased glycolysis, and diminished the ability of 
glucose to stimulate its own uptake and disposal [33, 34], which is a very confusing 
message. Yet if we unpick this, it may provide some clarity to the underlining 
metabolic response to hypoxia. We suggest that hypoxia stimulates a stress pathway 
for glycolysis while blocking insulin facilitated glucose uptake, providing a reason for 
the reduction in glycogenesis seen in the work of Louis & Punjabi [33]. However, this 
would not explain the decrease in the ability of glucose to stimulate its own transport, 
measured in Louis & Punjabi, [33] work as glucose effectiveness (SG). However, SG 
is a mixed parameter that measures the ability of glucose to affect its own transport by 
mass action  at basal insulin concentrations and is therefore dependant, to an extent, 
on insulin. 
 
In other reports insulin resistance increases with hypoxia in genetically leptin 
deficient obese mice [15], respiratory conditions [35] and healthy humans [14, 36]. 
However, a closer look at the underlining data from these reports is informative and 
helps unpick more detail around the response of different models of hypoxia. For 
example, the increase in insulin resistance noted in the Polotsky et al. [15] study, 
which used obese, leptin deficient mice, was completely abolished by acute leptin 
replacement. Leptin, an adipose tissue peptide hormone interacts with skeletal muscle 
[37], increasing fatty acid oxidation and reduces intramuscular stores of triglycerides 
[38] while improving insulin action [39]. There is evidence to show that a decrease in 
secondary lipid products, ceramide, diglyceride and long-chain fatty acyl CoA can 
reduce the inhibitor effect of fats on Akt mediated insulin signaling in skeletal muscle 
[reviewed; 96].  
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Using the typically regarded “gold standard” assessment of glucose tolerance 
(euglycemic – hyperinsulinemic clamp), Larsen et al. [40] found that insulin 
sensitivity decreased significantly in response to 2 days of altitude exposure (4559 m; 
~12% O2) with a reduction in glucose infusion rates to achieve euglycemia, from 9.8 
(1.1) to 4.5 (0.6) mg  kg
-1 
min
-1 
(P< 0.05). The same work did, however, show 
improvements in insulin action with altitude acclimatisation (7 day exposure) [40] 
suggesting a haemostatic balance between insulin secretion, insulin action and 
glucose disposal rates.  
From a cellular mechanistic point of view, hypoxia seems to induce insulin resistance 
in insulin sensitive tissue through the suppression of total and pAkt during basal 
conditions and with IGF-1 stimulation in C2C12 skeletal muscle cells [41]. Low 
oxygen treatment of C2C12 cells in vitro inhibits the PI3-kinase/Akt pathway by 
reducing IGF-I receptor (IGF-IR) sensitivity to growth factors [19], suggesting that 
hypoxia may interfere directly with key signaling transduction pathways in skeletal 
muscle. In addition, the same work showed that pGSK3αS21, pGSK3βS9, total GSK, 
pAkt
t308
, pAkt
s473
 and total Akt were all reduced following 48 hours of differentiation 
in C2C12’s while IRS-1 & -2 were unchanged under severe hypoxic treatment (O2 
~0.5%) [19]. This again suggests that hypoxia alters insulin signaling at a post 
receptor - intracellular level and / or via an indirect action on IGF-1 receptor. All of 
this data taken together demonstrates that hypoxia, at least in in vitro models, has the 
ability to alter insulin signaling down stream of IRS. It is worth mentioning that the 
relevance of culture models to whole body physiological responses must be read with 
a degree of caution as the level of hypoxia (i.e. O2 ~0.5-5%) commonly used in vitro 
work is unlikely to be seen at the tissue level of skeletal muscle in humans subjected 
to whole body hypoxia (i.e. O2 ~ 12-15%). However, phosphorylation of Akt
s473
 and 
GSK-3βs9, obtained from vastus lateralis using standard muscle biopsy techniques, 
were decreased in chronic obstructive pulmonary disease (COPD) patients presenting 
with hypoxemia [resting arterial Po2 = 57.0 (1.0) mmHg] [42]. This evidence suggests 
that chronic hypoxemia seen in disease conditions may be involved in the progression 
of insulin resistance. However, these findings were not supported in skeletal muscle 
extracted from C57BL/6J mice treated with 10% O2 for 4 weeks [43].  Interpretations 
from human work are also mixed with Etheridge et al [94] showing no change in 
pAkt
s473 
during hypoxia while D’Hulst showed that 11% inspired O2 reduced pAkt
s473 
[95]. The difference between these studies may be explained by the basal nutritional 
status of the subjects. Etheridge and colleagues [94] examined their subjects in a 
fasted state, where as those in D’Hulst and colleagues study [95] consumed a meal 40 
minutes prior to the start of the experimental trial.  
Lastly, whole body hypoxic treatment seen in in vivo research is likely to affect a 
variety of tissue types, not just skeletal muscle. Obesity is characterized by adipose 
tissue expansion that results in pockets of localised tissue hypoxia in the most affected 
areas. In addition, there is evidence that localized hypoxia seen in adipose tissue may 
result in systemic metabolic dysfunction seen in different tissue types, further 
highlighting the complexity of the issue. For this reason the effects of hypoxia on fat 
tissue has been widely researched. In an attempt to isolate the effects of hypoxia on 
adipocytes, Regazzetti et al., [45] treated 3T3-L1 cells with 1% O2 and showed that 
Akt, pAS160 content and glucose transport rates were all decreased under these 
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conditions and that this stress further inhibited insulin signaling and glucose uptake in 
response to insulin treatment [45]. Thus the response of whole body metabolism to 
hypoxia may be a systemic condition. Nevertheless, hypoxia clearly alters metabolism 
and affects intracellular signaling of tissues which is likely to serve the goal of 
reducing energy consuming processes (i.e. glycogen formation and protein synthesis) 
and up-regulate ATP producing (i.e. glycolysis) and cell survival mechanisms.  
 
Hypoxia Stimulates Glucose Uptake Independent to the Actions of Insulin  
Insulin and contractile activity stimulate glucose disposal in skeletal muscle using 
separate, independent signaling pathways [46] with insulin mediated via Akt-AS160 
and contraction via AMPK-AS160. Hypoxia also activates glucose transport using the 
same signaling pathway to that of contractile activity [47] (Figure 1). Indeed, glucose 
transport has been shown to be additive when either hypoxia or contractile activity are 
coupled with insulin, whereas hypoxia and contractile activity are not [47, 48]. The 
ability of hypoxia to stimulate glucose disposal, independently of contractile activity 
has been documented in both animal [47, 49] and in vitro work using isolated human 
muscle tissue [46, 48].   
In 1958 Randle and Smith published data showing that hypoxia, induced via the 
chemical inhibition of oxidative metabolism, resulted in a loss of cellular potassium 
(K
+
), inhibition of active K
+
 uptake, coupled with stimulation of ATP-sensitive K
+
 
channels, an increase in cellular ATP/AMP ratio and ultimately an increase in 
extracellular K
+
 levels [50, 51]. These ion changes lead to membrane depolarisation, 
opening of voltage-gated Ca
2+
 channels and an increase in SR Ca
2+
 release in a 
manner similar to muscle contraction. Hypoxia is known to reduce oxygen 
availability, inhibit mitochondrial respiration [52] and increase AMP:ATP ratio [53], 
resulting in increased cytolytic AMP availability and greater AMP binding capacity to 
the  regulatory subunit, activation of AMPK [54] and stimulation of glucose 
transport [47].  
It is clear that hypoxia (at least during the stress) encourages glucose uptake in skeletal 
muscle via AMPK and Ca
2+
-dependant mechanisms. Evidence shows that Ca
2+
 can 
activate glucose uptake in a calmodulin-dependent protein kinase (CaMKK) / AMPK 
dependent manner [55] identical to mechanisms responsible for contraction induced 
glucose uptake in muscle [47, 46]. Although elevations in intracellular Ca
2+ 
levels may 
also provoke AMPK-independent glucose transport as glucose transport activity is 
increased during sub-contraction increases in muscle Ca
2+
 when stimulated with 
caffeine [54]. Activation of glucose uptake with hypoxia is facilitated by an increase 
in the activation of GLUT-1 pre-existing in the cell membrane [52] while stimulating 
translocation of intracellular GLUT-1 and -4 to the sarcolemma [47, 52]. 
 
AMPK is essential for hypoxia-induced glucose transport [24]. Using AMPK2 
deficient rodents (Tg-KD1), Mu et al. [24] showed that glucose transport was 
completely blocked under hypoxia when compared to wild-type counter-parts. 
Furthermore, the hypoxia-induced increase in membrane bound GLUT-4 content was 
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reduced in the same Tg-KD1 mice [24]. These findings have been extended into 
human work, with Wadley et al. [56] showing that AMPK2 activity and AMPK 
Thr
172
 phosphorylation were significantly increased during exercise in hypoxia when 
compared to the same relative exercise intensity in normoxic conditions.  The rate of 
glucose disappearance was also found to be significantly higher in the hypoxic trial, 
suggesting that hypoxia, when combined with exercise, has a greater effect on AMPK 
activity and glucose transport over exercise alone [56] and that hypoxia mediates 
glucose uptake via a pathway dependent [partly] on AMPK in humans.  
 
Much of the work discussed above is in cell culture models or animal work yet the 
findings from a whole body perspective seem to align well with this data. Using 
isotope methodology Brooks et al. [32] concluded that altitude acclimatisation (4300 
m) increased glucose disappearance (Rd) and metabolic clearance rates (MCR) during 
both exercise and resting states when compared to sea-level values. Interestingly, 
insulin concentrations were unchanged from pre altitude levels [32], suggesting an 
increase in contraction stimulated glucose transport or improved insulin sensitivity at 
altitude. In support Johnson et al. [57] demonstrated that acute altitude exposure (2-
40 hr) resulted in progressive hypoglycemia, which was attributed to increased 
glucose clearance and oxidation, which was confirmed by Cooper et al. [58]. Using 
an oral glucose tolerance test, Lee et al. [59] showed that high altitude exposure (3 
days) significantly improved glucose tolerance in sea-level natives and in type 2 
diabetics. Prior hypoxic exposure is also known to increase two compartment models 
of insulin sensitivity [23] with acute intermittent hypoxia shown to improve glucose 
control in patients with type 2 diabetes [60]. 
  
A study by Forbes, in 1936, was one of the first to suggest that altitude could alter the 
manner in which glucose is handled by health sea-level residents [61]. This work 
showed that blood glucose clearance was increased during an OGTT administrated at 
high altitude. Following this work, research has not only confirmed Forbes [61] 
conclusions, but looked to extend it by showing that long-term exposure to simulated, 
or actual altitude results in; 1) reduced fasting plasma glucose concentrations [62-65] 
and 2) elevated glucose clearance rates during an intravenous glucose load [62, 64].  
 
A recent review concluded that long-term exposure to altitude results in improved 
glycemic control and lower prevalence of obesity and diabetes [66]. It is generally 
recognised that high altitude natives have a reduced prevalence of type 2 diabetes [63, 
67, 68] while the same population also display lower glucose concentrations [50.6 
(3.7) mg / dL] compared to sea-level residents [73.4 (4.0) mg / dL] when monitored 
during a ~12 hour period [69]. Despite having a high prevalence of obesity (BMI ≥ 
30kg / m
2
) rural Aymara natives (living at altitudes 2050-4250 m) are also known to 
be at a reduced risk of developing type 2 diabetes [68]. These authors attributed this 
finding to near normal insulin values [mean (SD); 9.3 (10.2) µU / ml] and low levels 
of insulin resistance [HOMAIR 1.8 (2.4)] [68].  
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Studies elsewhere have shown that long-term altitude exposure is linked with low 
glucose and insulin concentrations [70, 71]. Ri-Li et al., [72] concluded that Tibetan 
natives exhibit genetic modification (namely; PPARA, encoding PPARα) that 
increases glycolysis and decreases hepatic gluconeogenesis and free fatty acids. The 
authors further suggest that these adaptations may help to reduce diabetic and obesity 
risk [72]. Indirect evidence also shows inverse correlations between altitude natives 
and the risks of diabetes [73].  
 
 
Insulin resistance seen with hypoxia may merely reflect the use of a separate 
preferential pathway for glucose uptake 
The literature surrounding hypoxic induced changes in glycemic control, insulin 
resistance and type 2 diabetes may appear confusing and conflicting. How is it that 
hypoxia can seemingly cause insulin resistance while at the same time stimulate 
glucose uptake? The answer may be attributed to the duration of stress (minutes vs 
days), the host (i.e. altitude natives vs obese type 2 diabetics), the nutritional status of 
the host, the model under investigation (cell culture vs whole body), the degree of 
adaptation to the conditions and the measurement methods under use (hyperinsulimic- 
euglycemic clamp during hypoxia). If we can put all of these matters to one side for 
the time being and remember that hypoxia is a stress and that under such conditions, 
respiring tissue seems to switch to a stress mediated pathway acting independently, in 
this context, to insulin. This has been demonstrated indirectly through the suppression 
of insulin action [14, 16] and insulin secretion with hypoxic treatment [74], while at 
the same time, encouraging glucose uptake [32, 47]. We suggest that under hypoxic 
condition a preferential Ca
2+ 
/ AMPK-dependent pathway maybe up-regulated to 
maintain ATP production (glycolysis) and reduce ATP consuming mechanisms 
(protein & glycogen synthesis). This is partly supported by the literature that shows 
hypoxia and exercise stimulate glucose uptake via AMPK-AS160 [24, 75] while 
insulin acts through Akt-AS160  [76-78] mediated pathways. Comparisons with 
exercise are used, as this stimulus is known to activate glucose uptake using the same 
mechanisms associated with hypoxia.  
Hypoxia has been shown, in cell lines, to impair IRS-1 [45], Akt and PI3-kinase 
activity [19, 41], yet the same stress increases glucose uptake, intracellular Ca
2+ 
levels, 
CaMKK, AMPK-AS160 and GLUT-4 muscle content. In support, whole body 
experimental work would suggest that hypoxia induces insulin resistance while also 
stimulating glucose disposal. This review will now try to explain these contrasting 
views while proposing a working hypothesis as to the role of hypoxia in glucose 
metabolism.  
 
Firstly, the findings from whole body studies, that hypoxia causes insulin resistance, 
may be the product of increased insulin release combined with a decrease in insulin 
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action at the site of insulin sensitive target tissue. Indeed, elevated circulating insulin 
concentration and perceived insulin resistance with hypoxic treatment [79], is a 
finding that has some support. In addition, hypoxia is known to encourage insulin 
synthesis and release by pancreatic β-cells [80], creating an acute or chronic 
physiological state resulting in blood insulin accumulation and perhaps perceived 
insulin resistance. This combined with decreased insulin-stimulated glucose disposal 
and insulin signaling is likely to result in such conclusions. Further, the introduction 
of exogenous insulin, which is implicit in the hyperinsulinemic-euglycemic clamp 
method, may further aggravate the problem. Hyperinsulinemia has been demonstrated 
to inhibit IRS-1  / Akt activity in vitro [11] and cause insulin resistance in vivo [10, 17, 
81, 82]. Thus the use of the two-step hyperinsulinemic-euglycemic clamp which 
delivers a low insulin, (20 mU  m
-2 

 
min
-1
 for 180 min) followed by a high insulin 
dose (80 mU  m
-2 

 
min
-1
 for 120 min)  [93] may be a better approach to assessing 
insulin sensitivity in insulin resistant  / obese populations under additional 
environmental hypoxia. Importantly, Lecoultre et al. [93] work measured insulin 
sensitivity under normoxic conditions both before and after the ten-day treatment. 
Thus the clamp method here was employed following rather than under hypoxic 
conditions.  
 
Here we suggest that combining hypoxia with insulin accumulation, through its 
exogenous introduction and / or decreased insulin action, would indicate that the use 
of clamp methods are not necessarily an appropriate model for assessing insulin 
sensitivity under non-steady state conditions such as exercise or hypoxia. Indeed, the 
introduction of exogenous insulin with the hyperinsulinemic-euglycemic clamp, and a 
decrease in insulin signaling activity [17] due to a heavier reliance on contraction-
stimulated glucose uptake may merely reflect a shift towards a preferential pathway 
for glucose uptake resulting in plasma insulin accumulation.  
 
There may also be some intracellular cross-talk between the two prominent regulatory 
pathways involved in controlling glucose uptake under hypoxic conditions which 
results in up-regulation of AMPK-AS160 that coexists with a reduction in insulin 
mediated glucose transport. There is certainly some good evidence that hypoxia may 
cause insulin resistance, however it is proposed that this may be a product of a 
competition between pathways (i.e. a preferential use of the AMPK pathway under 
hypoxic stress) with a subsequent decrease in insulin signaling rather than insulin 
resistance pre se. This is supported by the direct inhibition of insulin stimulated 
glucose transport with treatment of the calmodulin antagonist N-(6-aminohexyl)-5-
chloro-1-naphthalenesulfonamide (W-7) [83]. Calmodulin (CaM) is a calcium-
binding protein that modifies target proteins [84] such as AMPK [85]. In addition this 
Ca
2+
/calmodulin complex is considered to be involved in hypoxic induced glucose 
uptake [88] with AMPK activation increased with the overexpression of 
Ca
2+
/calmodulin-dependent protein kinase (CaMKK) [85]. In addition, the down 
regulation of CaMKK using RNA interference, inhibits AMPK activity [85], 
implicating CaMKK in AMPK regulation and glucose uptake [46, 54, 86, 87].  
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Hypoxia increases intracellular free Ca
2+
 [47] and subsequently CaMKK [88] with the 
ensuing calcium signaling directly inhibiting insulin-stimulated glucose transport. The 
proposed mechanisms involved in this inhibition are detailed in Figure 2(A). Youn et 
al. [83] showed that the effects of W-7 treatment on glucose transport were additive 
with hypoxia and that the same treatment reduced insulin mediated glucose transport 
in skeletal muscle. Furthermore, a fivefold increase in insulin concentration was 
required to produce a half-maximal stimulation in glucose transport [83]. All of this 
data combined indicates that hypoxia-induced glucose transport is not hindered by W-
7 treatment and that free intracellular Ca
2+
 may directly or indirectly inhibit insulin 
signaling. This data suggests that the up-regulation of glucose uptake by hypoxia may 
result in insulin accumulation systemically, by the effect of reduced processing of 
insulin into insulin fragments by insulin sensitive tissues. The latter point is important 
as this may lead to the conclusion that hypoxia causes a reduction in insulin action 
and results in glucose intolerance due to plasma insulin accumulation.  
 
Further evidence that the regulatory pathways that affect glucose transport work 
independently of each other, yet have the ability to communicate with one another, 
comes from experiments with 5-aminoimidazole-4-carboxamide ribonucleoside 
(AICAR), which activates AMPK while inhibiting insulin-stimulated glucose 
transport in 3T3-L1 adipocytes [89]. Incubating C2C12 skeletal muscle cells or rat 
extensor digitorum longus (EDL) muscle with insulin increases phosphorylation of 
AMPK at 
S485/491 
[90].  Phosphorylation of AMPK at 
S485/491 
directly inhibits AMPK 
activity. Indeed,
 
insulin stimulation of Akt results in pAMPK
S485/491
, leading to a 
reduction in AMPK activity [91] [Figure 2(B)]. This phosphorylation can prevent 
subsequent activation of AMPK
Th172
 by LKB1 and that pAMPK at 
S485/491 
by insulin 
reduces the interaction between AMPK and LKB1 [92] suggesting that insulin 
inhibition of AMPK occurs upstream and that insulin, via the activation of Akt, may 
directly interfere with AMPK phosphorylation and activity [91], while presumably 
reducing AMPK-dependent glucose uptake. Collectively, these data again suggest that 
a potential cross-talk interplay between the Akt and AMPK pathways may exist and 
that the down regulation of insulin signaling by hypoxia reduces the Akt inhibitory 
effect on pAMPK
S485/491
.  
 
Concluding remarks  
Evidence that hypoxia leads to insulin resistance has been widely published. There 
seems little doubt that acute hypoxia interferes with insulin signaling / action in 
skeletal muscle. Yet the same stress is also partnered with increased glucose uptake in 
a largely insulin independent manner. In vivo research presents data which is 
conflicting, some showing improvements in insulin sensitivity while others suggest 
that hypoxia induces insulin resistance. At a cellular level, there seems to be less 
controversy. Hypoxia increases glucose uptake and activates Ca
2+
/AMPK mediated 
pathways in response to low oxygen tension in both cell culture models and ex vivo 
skeletal muscle. Yet, the same stress seems to decrease receptor and post-receptor 
activity of key insulin signaling intermediates. Firstly, we suggest that hypoxia does 
indeed down-regulate insulin signaling, at least in skeletal muscle, and that a 
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reduction in this pathway ultimately results in insulin accumulation and results in the 
misleading detection of insulin resistance, making the in vivo modelling of insulin 
sensitivity under hypoxic conditions difficult. Particularly with the introduction of 
high physiological concentrations of exogenous insulin as associated with the 
hyperinsulinemic clamp approach. It seems clear that the two major pathways 
involved in glucose transport and metabolism in skeletal muscle, insulin- and 
contraction-dependant mechanisms, work separately and that upon the application of 
a stress (i.e. hypoxia) cells shift towards a preferred AMPK-dependant mechanism 
and away from insulin. This is merely a working hypothesis but is not a new notion 
with Cartee et al. [47] and Azevedo et al. [47] clearly demonstrating that hypoxia 
activates the contraction-stimulated pathway to facilitate glucose transport and that 
this occurs independent to the actions of insulin.  
It is important that we develop a better understanding of glucose transport 
mechanisms and the causes of insulin resistance as this has clear clinical applications. 
Furthermore, it may be that hypoxia has a part to play in the therapeutic treatment of 
type 2 diabetes rather than being implicated in its progression. Conclusions from in 
vitro work are important but limited in application. At a whole body level, many of 
the studies that demonstrate a link between insulin resistance and hypoxia have done 
so while measuring this parameter under low oxygen conditions, which, while a valid 
approach in terms of external validity, makes the modelling of insulin sensitivity 
difficult. Thus developing new in vivo approaches to modelling insulin sensitivity, 
such as the two-step clamp method may increase our understanding of the role 
hypoxia plays in glucose transport and glycemic control.  Glucose effectiveness, as 
measured by the labelled intravenous glucose tolerance test (IVGTT) quantifies the 
ability of glucose to transport itself at basal insulin concentration. This technique also 
separates glucose control into measures of hepatic glucose production and disposition 
index, and as such, may provide a useful approach to assessing the true effects of 
hypoxia on insulin and hypoxic mediated glucose disposal.   
The question of whether hypoxia causes insulin resistance, or not, is a complex one. 
At a cellular level, the evidence clearly shows that hypoxia increases glucose uptake, 
and that this coexists with an inhibition of insulin signaling. The authors propose that 
under hypoxic conditions, at least acutely, glucose transport is increased using cellular 
pathways that operate independent to insulin thus given the impression of insulin 
resistance. Given the current research, the authors conclude that hypoxia may 
decrease insulin signaling but may not induce whole body insulin resistance.  
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Figure 1: Insulin & contraction signaling pathways during GLUT-4 recruitment & 
translocation. Adapted from Mackenzie and Elliott [44].  
Abbreviations:  
IRS, insulin receptor substrate; PI3-K, class IA phosphatidylinositol 3-kinase; PIP2, 
phosphatidylinositol (4,5)-bisphosphate; PIP3, phosphatidylinositol 3,4,5-
trisphosphate; PDK1, phosphoinositide-dependent protein kinase-1; Akt, 
serine/threonine protein kinase; AS160, 160 kDa Akt substrate; GLUT-4, glucose 
transporter 4; GSV, GLUT-4 storage vesicle; Rab-GAP, Rab-GTPase-activating 
protein; Rab-GDP, guanosine-50-diphosphate-loaded Rab; Rab-GTP, guanosine-50-
triphosphate-loaded Rab; CaMKK, Ca
2+
/calmodulin-dependent protein kinase kinase; 
LKB1, Serine/threonine kinase 11; STRAD, putative kinase; MO25, mouse protein 
25/scaffold protein; AMPK, 5′-monophosphate-activated protein kinase; Thr172, 
phosphorylated AMPKα at threonine 172; AMP, adenosine monophosphate; ATP, 
adenosine triphosphate; P, phosphorylated site.  
 
 
 
 
 
 
Figure 2: Proposed communication between hypoxia- and insulin-stimulated glucose 
transport mechanisms. Figure 2 (A) displays the proposed hypoxia induced Ca
2+
 / 
CaMKK inhibition on insulin signaling & insulin-stimulated glucose transport. 
Glucose transport is facilitated via an AMPK-dependent mechanism in response to 
hypoxia despite decreased Akt activity. Figure 2 (B) glucose transport mechanisms in 
response to insulin. Figure 2(B) also displays Akt mediated AMPK phosphorylation 
at Ser
485/491
 [91] resulting in AMPK inhibition.  
 
 



